In the landscape of cancer treatment, clinical trials stand as beacons of hope, offering potential breakthroughs and extended lifespans for patients. Yet, despite the multitude of trials conducted annually in the United States, only a small fraction of eligible patients—3% to 5%—actually enroll in these investigational treatments. Triomics, a pioneering AI startup, aims to revolutionize this process, promising to drastically reduce the time it takes for doctors to match patients with appropriate trials.
Founded by former MIT biotech researcher Sarim Khan and AI scientist Hrituraj Singh, Triomics emerged in 2021, propelled by a shared vision of leveraging generative AI and LLMs to streamline the arduous task of trial matching. Recognizing the overwhelming burden faced by oncology medical staff in navigating complex trial criteria amidst time constraints, Khan and Singh embarked on a mission to harness technology for more efficient patient-trial pairing.
What is Triomics
Triomics’ flagship solution, OncoLLM, tailored for cancer centers and hospital oncology departments, stands as a testament to their dedication. By parsing through electronic health records (EHR) in mere minutes, OncoLLM identifies suitable trials, sparing medical professionals the hours typically spent in manual review. This acceleration not only enhances patient access to trials but also mitigates the risk of missed eligibility windows due to staff shortages.
The impact of Triomics extends beyond trial matching; it permeates various facets of oncology care. Beyond expediting trial enrollment, OncoLLM assists in patient visit preparation and facilitates seamless submission of cancer data to regulatory agencies, equipping medical teams with comprehensive insights for informed decision-making.
Triomics’ momentum continues to surge, with six cancer centers and hospitals already integrating or piloting their platform. Bolstered by a recent $15 million Series A funding round from Lightspeed, Nexus Venture Partners, General Catalyst, and Y Combinator, Triomics is poised for exponential growth, aiming to double its customer base by year’s end.
While Triomics faces competition from fellow AI startups like Deep 6 AI, QuantHealth, and Trajectory, its focused approach on processing extensive datasets specifically for cancer centers sets it apart. With its steadfast commitment to innovation and transformative impact, Triomics epitomizes the convergence of technology and healthcare, catalyzing progress in the fight against cancer.
